The chemopreventive effects of the essential dietary trace element Selenium (Se) is known to impact cancer incidence and mortality, however its antiangiogenic role makes it a possible novel and ideal chemomodulator candidate. Unlike other antiangiogenic agents, Se is well-tolerated at a relatively high daily dose of 7200

Public Health Relevance

The commonality of the antiangiogenic and vascular maturation activity of dietary supplement selenium (Se) through HIF-1 degradation via modulation of reactive oxygen species will be investigated in two histologically distinct human tumor xenografts from three different cancer sites - lungs, head and neck, and, colon, for understanding its'synergistic interaction with conventional cancer chemotherapy where often natural supplements are contraindicated. Successful completion of the studies proposed will establish the role of Se in inhibiting HIF-11 in cancer and other disease for a disease free maintenance of life across the life span of an individual.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Davis, Cindy D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Tóth, Károly; Chintala, Sreenivasulu; Rustum, Youcef M (2014) Constitutive expression of HIF-? plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma. Appl Immunohistochem Mol Morphol 22:642-7
Chintala, Sreenivasulu; Najrana, Tanbir; Toth, Karoly et al. (2012) Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. BMC Cancer 12:293
Bhattacharya, Arup; Turowski, Steve G; San Martin, Ivan Dominguez et al. (2011) Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Res 31:387-93
Bhattacharya, Arup (2011) Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv 8:749-63
Hu, Yan; Spengler, Mary L; Kuropatwinski, Karen K et al. (2011) Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. Oncotarget 2:1279-90
Vaughan, Mary M; Toth, Karoly; Chintala, Sreenivasulu et al. (2010) Double immunohistochemical staining method for HIF-1alpha and its regulators PHD2 and PHD3 in formalin-fixed paraffin-embedded tissues. Appl Immunohistochem Mol Morphol 18:375-81
Chintala, Sreenivasulu; Tóth, Károly; Cao, Shousong et al. (2010) Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol 66:899-911
Rustum, Youcef M; Toth, Karoly; Seshadri, Mukund et al. (2010) Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. J Oncol 2010:396286
Bhattacharya, Arup; Tóth, Károly; Sen, Arindam et al. (2009) Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin Colorectal Cancer 8:155-62